Compare Amphastar Pharmaceuticals Inc (AMPH) vs BioNano Genomics Inc (BNGO) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

BNGO trades at $1.20, up 5.26% today, but technical signals are bearish with moving averages indicating selling pressure. The company reported a net loss of -$26.40M in 2025 despite beating EPS estimates in recent quarters. Recent news highlights leadership changes and growing adoption of its optical genome mapping technology, with 67% year-over-year growth in studies presented at ESHG 2026 (GlobeNewswire, June 18, 2026).

The outlook remains challenged by persistent losses and negative cash flow, though low valuation ratios (P/S 0.31, P/B 0.37) may attract value investors. Analyst sentiment is cautiously optimistic with 57% buy ratings, but execution risks and profitability concerns pose significant headwinds for near-term stock performance.